Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults

NCT01324752 is registered in ClinicalTrials.gov with Vifor Pharma as lead sponsor.

NCT NCT01324752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01324752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults
Lead sponsor
Vifor Pharma
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
June 30, 2011
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

drug interaction potentiation